

The Patented Medicines Prices Review Board is consulting on new guidelines

November 21, 2023

The Patented Medicines Prices Review Board (PMPRB) has [launched the first phase](#) of consultations on its new Guidelines, inviting feedback through upcoming policy roundtables or through written submissions.

Previously, we discussed the [amendments made to the Patented Medicines Regulations](#), which govern PMPRB activity, and how the most controversial parts of those amendments were later [struck down by the Federal Court](#) as being *ultra vires* the *Patent Act*. The remaining amendments changed the basket of comparator countries from 7 to 11, while also removing the United States and Switzerland.

In early fall, the [PMPRB announced](#) that it would adopt the [Amended Interim Guidance](#) during the consultation period, indicating that it would “approach the consultation with a fresh and open mind.”

The PMPRB published a [scoping paper for the consultations on the Board’s Guidelines](#), which sets out the themes on which it is seeking stakeholder views:

1. Efficient monitoring of prices without price setting
2. Transition to PMPRB11 – new versus existing medicines
3. Price reviews during product life cycle
4. Investigations and referral to hearing
5. Relation to pan-Canadian health partners, insurers (private and public); and alignment with broader government initiatives
6. Engaging with patients, health practitioners, pharmacy, and other stakeholders

More detail on each of these themes, as well how to submit feedback and information about the roundtable, can be found in the scoping paper at the link above,.

To participate in one of the roundtables, you must complete the [Policy Roundtable Registration Form](#) by **Nov. 24, 2023**. Written submissions are being accepted until **Dec. 20, 2023**.

By

[Beverley Moore](#), [Chantal Saunders](#)

Expertise

[Intellectual Property, Health Care & Life Sciences](#)

BLG | Canada's Law Firm

As the largest, truly full-service Canadian law firm, Borden Ladner Gervais LLP (BLG) delivers practical legal advice for domestic and international clients across more practices and industries than any Canadian firm. With over 800 lawyers, intellectual property agents and other professionals, BLG serves the legal needs of businesses and institutions across Canada and beyond – from M&A and capital markets, to disputes, financing, and trademark & patent registration.

blg.com

BLG Offices

Calgary

Centennial Place, East Tower
520 3rd Avenue S.W.
Calgary, AB, Canada
T2P 0R3

T 403.232.9500
F 403.266.1395

Ottawa

World Exchange Plaza
100 Queen Street
Ottawa, ON, Canada
K1P 1J9

T 613.237.5160
F 613.230.8842

Vancouver

1200 Waterfront Centre
200 Burrard Street
Vancouver, BC, Canada
V7X 1T2

T 604.687.5744
F 604.687.1415

Montréal

1000 De La Gauchetière Street West
Suite 900
Montréal, QC, Canada
H3B 5H4

T 514.954.2555
F 514.879.9015

Toronto

Bay Adelaide Centre, East Tower
22 Adelaide Street West
Toronto, ON, Canada
M5H 4E3

T 416.367.6000
F 416.367.6749

The information contained herein is of a general nature and is not intended to constitute legal advice, a complete statement of the law, or an opinion on any subject. No one should act upon it or refrain from acting without a thorough examination of the law after the facts of a specific situation are considered. You are urged to consult your legal adviser in cases of specific questions or concerns. BLG does not warrant or guarantee the accuracy, currency or completeness of this publication. No part of this publication may be reproduced without prior written permission of Borden Ladner Gervais LLP. If this publication was sent to you by BLG and you do not wish to receive further publications from BLG, you may ask to remove your contact information from our mailing lists by emailing unsubscribe@blg.com or manage your subscription preferences at blg.com/MyPreferences. If you feel you have received this message in error please contact communications@blg.com. BLG's privacy policy for publications may be found at blg.com/en/privacy.

© 2026 Borden Ladner Gervais LLP. Borden Ladner Gervais LLP is an Ontario Limited Liability Partnership.